Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Thiogenesis Therapeutics Corp., a clinical-stage biopharmaceutical company, has engaged Capital Analytica for investor relations services to enhance social media presence and investor engagement. The company agreed to pay quarterly fees and grant stock options under the new agreement. Additionally, Thiogenesis has issued restricted share units to an officer, with both stock options and RSUs subject to regulatory approval.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money